Engineered Materials for Cancer Immunotherapy.

[1]  HighWire Press,et al.  Molecular cancer therapeutics , 2016 .

[2]  E. Tasciotti,et al.  Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. , 2015, Nature materials.

[3]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[4]  J. Sunshine,et al.  Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. , 2015, Small.

[5]  S. Mitragotri,et al.  Monocyte-mediated delivery of polymeric backpacks to inflamed tissues: a generalized strategy to deliver drugs to treat inflammation. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Youngjin Choi,et al.  Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.

[7]  S. B. Stephan,et al.  Biopolymer implants enhance the efficacy of adoptive T cell therapy , 2014, Nature Biotechnology.

[8]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[9]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[10]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[11]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[12]  H. Vandenburgh,et al.  Biphasic Ferrogels for Triggered Drug and Cell Delivery , 2014, Advanced healthcare materials.

[13]  C. Löwik,et al.  Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[14]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[15]  Paula T. Hammond,et al.  Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-by-Layer (LbL) Nanoparticles , 2014, ACS nano.

[16]  Tarek R. Fadel,et al.  A carbon nanotube-polymer composite for T-cell therapy. , 2014, Nature nanotechnology.

[17]  K. Anderson,et al.  Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens. , 2014, Immunobiology.

[18]  K. Cibulskis,et al.  Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. , 2014, Blood.

[19]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[20]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[21]  P. Sharma,et al.  Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy , 2014, The Journal of experimental medicine.

[22]  C. Sheridan.  Immune-checkpoint inhibitors march on, now in combinations , 2014, Nature Biotechnology.

[23]  R. Noelle,et al.  VISTA Regulates the Development of Protective Antitumor Immunity. , 2014, Cancer research.

[24]  G. Dranoff,et al.  Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. , 2014, Cancer research.

[25]  David J Mooney,et al.  Injectable, porous, and cell-responsive gelatin cryogels. , 2014, Biomaterials.

[26]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[27]  M. Nango,et al.  Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. , 2014, Biochemical and biophysical research communications.

[28]  J. Hubbell,et al.  Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes , 2014, Cancer Immunology Research.

[29]  M. Butler,et al.  Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy , 2014, Immunological reviews.

[30]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[31]  D. Teachey,et al.  T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL , 2013 .

[32]  P. Romero,et al.  Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. , 2013, Cancer research.

[33]  G. Trinchieri,et al.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. , 2013, The Journal of clinical investigation.

[34]  E. Nelson,et al.  Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. , 2013, ACS nano.

[35]  V. Cardile,et al.  Evaluation of new amphiphilic PEG derivatives for preparing stealth lipid nanoparticles , 2013 .

[36]  L. Ferrucci,et al.  Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy , 2013, The Journal of experimental medicine.

[37]  C. Figdor,et al.  Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy , 2013 .

[38]  F. Guillemin,et al.  Surface chemistry architecture of silica nanoparticles determine the efficiency of in vivo fluorescence lymph node mapping. , 2013, ACS nano.

[39]  David J Mooney,et al.  Inflammatory Cytokines Presented from Polymer Matrices Differentially Generate and Activate DCs In Situ , 2013, Advanced functional materials.

[40]  S. Dhar,et al.  Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. , 2013, ACS nano.

[41]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[42]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[43]  F. Padilla,et al.  Acoustic droplet-hydrogel composites for spatial and temporal control of growth factor delivery and scaffold stiffness. , 2013, Acta biomaterialia.

[44]  Qiang Zhang,et al.  Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly(amidoamine) for siRNA delivery. , 2013, Biomaterials.

[45]  Tingmei Chen,et al.  Hydrazinocurcumin Encapsuled Nanoparticles “Re-Educate” Tumor-Associated Macrophages and Exhibit Anti-Tumor Effects on Breast Cancer Following STAT3 Suppression , 2013, PloS one.

[46]  J. Hubbell,et al.  Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. , 2013, Biomaterials.

[47]  B. Shalmon,et al.  Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies , 2013, Clinical Cancer Research.

[48]  P. Stayton,et al.  pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. , 2013, ACS nano.

[49]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  Sharon H Chou,et al.  Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity , 2013, Cancer Immunology, Immunotherapy.

[51]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[52]  M. Rahimi,et al.  Temperature-sensitive polymer-coated magnetic nanoparticles as a potential drug delivery system for targeted therapy of thyroid cancer. , 2012, Journal of biomedical nanotechnology.

[53]  David J Mooney,et al.  Injectable preformed scaffolds with shape-memory properties , 2012, Proceedings of the National Academy of Sciences.

[54]  R. Flavell,et al.  Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.

[55]  J. Hubbell,et al.  Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. , 2012, Biomaterials.

[56]  J. Ho,et al.  Photocontrolled targeted drug delivery: photocaged biologically active folic acid as a light-responsive tumor-targeting molecule. , 2012, Angewandte Chemie.

[57]  Changyou Gao,et al.  Uptake of hydrogel particles with different stiffness and its influence on HepG2 cell functions , 2012 .

[58]  G. Prendergast,et al.  IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.

[59]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[60]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[61]  D. Speiser,et al.  Vaccination‐induced functional competence of circulating human tumor‐specific CD8 T‐cells , 2012, International journal of cancer.

[62]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[63]  Ali Khademhosseini,et al.  Microfabrication of complex porous tissue engineering scaffolds using 3D projection stereolithography. , 2012, Biomaterials.

[64]  R. Steinman.  Decisions about dendritic cells: past, present, and future. , 2012, Annual review of immunology.

[65]  J. Banchereau,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[66]  W. Jiskoot,et al.  Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[67]  Paresh Chandra Ray,et al.  Multifunctional plasmonic shell-magnetic core nanoparticles for targeted diagnostics, isolation, and photothermal destruction of tumor cells. , 2012, ACS nano.

[68]  D. Irvine,et al.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.

[69]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[70]  W. Paul,et al.  Bridging Innate and Adaptive Immunity , 2011, Cell.

[71]  Hao Liu,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[72]  Michael J. Sailor,et al.  Bioresponsive Mesoporous Silica Nanoparticles for Triggered Drug Release , 2011, Journal of the American Chemical Society.

[73]  L. Lazzarato,et al.  Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells , 2011, The Journal of experimental medicine.

[74]  J. Schlom,et al.  Viral vector-based therapeutic cancer vaccines. , 2011, Cancer journal.

[75]  W. Wrasidlo,et al.  Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. , 2011, Cancer research.

[76]  Jun Jiao,et al.  Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response , 2011, Nature nanotechnology.

[77]  D. Irvine,et al.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. , 2011, Biomaterials.

[78]  P. Ellis,et al.  Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial , 2011, Journal of Cancer Research and Clinical Oncology.

[79]  D. Mooney,et al.  Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines , 2011, Biomatter.

[80]  D. Keskin,et al.  Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. , 2011, Biomaterials.

[81]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[82]  S. Mitragotri,et al.  Cell‐Based Drug Delivery Devices Using Phagocytosis‐Resistant Backpacks , 2011, Advanced materials.

[83]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[84]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  J. Hubbell,et al.  Engineering complement activation on polypropylene sulfide vaccine nanoparticles. , 2011, Biomaterials.

[86]  Paula T Hammond,et al.  Tissue integration of growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants. , 2011, Biomaterials.

[87]  Soong Ho Um,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[88]  W. Jiskoot,et al.  Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[89]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[90]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[91]  E. Fikrig,et al.  TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis , 2010, The Journal of Immunology.

[92]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[93]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[94]  Soong Ho Um,et al.  Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.

[95]  N. Munshi,et al.  A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma , 2010, Haematologica.

[96]  Tarek R. Fadel,et al.  Clustering of stimuli on single-walled carbon nanotube bundles enhances cellular activation. , 2010, Langmuir : the ACS journal of surfaces and colloids.

[97]  R. Lai,et al.  Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy. , 2010, Molecular pharmaceutics.

[98]  P. Kantoff,et al.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  A. El-Kadi,et al.  The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. , 2010, Biomaterials.

[100]  David J Mooney,et al.  In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.

[101]  M. Bouxsein,et al.  β-Arrestin–Biased Parathyroid Hormone Ligands: A New Approach to the Development of Agents that Stimulate Bone Formation , 2009, Science Translational Medicine.

[102]  A. Friedman,et al.  An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme , 2009, Molecular Cancer Therapeutics.

[103]  Michael J Sailor,et al.  Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. , 2009, Small.

[104]  C. Drake,et al.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.

[105]  Shuming Nie,et al.  Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. , 2008, Small.

[106]  San-Yuan Chen,et al.  Instantaneous drug delivery of magnetic/thermally sensitive nanospheres by a high-frequency magnetic field. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[107]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[109]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[110]  Tarek R. Fadel,et al.  Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. , 2008, Nano letters.

[111]  T. Lawrence,et al.  “Re-educating” tumor-associated macrophages by targeting NF-κB , 2008, The Journal of experimental medicine.

[112]  H. Junginger,et al.  Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[113]  Monty Liong,et al.  Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. , 2008, ACS nano.

[114]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[115]  T. Fahmy,et al.  A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[116]  R. Tampé,et al.  Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation , 2008, Nature Immunology.

[117]  M. Ernstoff,et al.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. , 2008, Blood.

[118]  Baorui Liu,et al.  Thermo and pH Dual‐Responsive Nanoparticles for Anti‐Cancer Drug Delivery , 2007 .

[119]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[120]  D. Discher,et al.  Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.

[121]  Simon Benita,et al.  Targeting of nanoparticles to the clathrin-mediated endocytic pathway. , 2007, Biochemical and biophysical research communications.

[122]  P. Couvreur,et al.  Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells , 2007, Cellular and Molecular Life Sciences.

[123]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[124]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[125]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[126]  A. Rakhmilevich,et al.  Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects1 , 2006, The Journal of Immunology.

[127]  Sven Frokjaer,et al.  Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. , 2005, International journal of pharmaceutics.

[128]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  R. Day,et al.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer , 2005, Cancer Immunology, Immunotherapy.

[130]  P. Pandolfi,et al.  GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease , 2004, The Journal of experimental medicine.

[131]  O. Eremin,et al.  Dendritic cells are dysfunctional in patients with operable breast cancer , 2004, Cancer Immunology, Immunotherapy.

[132]  Mark M. Davis,et al.  T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.

[133]  A. Friedman,et al.  Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  I. Mellman,et al.  Activation of Lysosomal Function During Dendritic Cell Maturation , 2003, Science.

[135]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[136]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[137]  K. Beningo,et al.  Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. , 2002, Journal of cell science.

[138]  J. Norton,et al.  Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-121 , 2001, The Journal of Immunology.

[139]  C. Kurts,et al.  Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo1 , 2001, The Journal of Immunology.

[140]  K. Wucherpfennig,et al.  Anergy Induction by Dimeric TCR Ligands1 , 2001, The Journal of Immunology.

[141]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[142]  K. Rock,et al.  Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines , 1994, European journal of immunology.

[143]  A. Denman,et al.  Annual Review of Immunology , 1991 .

[144]  M. Mescher,et al.  Cell-sized, supported artificial membranes (pseudocytes): response of precursor cytotoxic T lymphocytes to class I MHC proteins. , 1986, Journal of immunology.

[145]  J. Hubbell,et al.  Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. , 2014, Biomaterials.

[146]  J. Sunshine,et al.  Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. , 2014, Biomaterials.

[147]  A. Tiwari.  Advanced Healthcare Materials , 2014 .

[148]  Jian Chen,et al.  RAFTsomes Containing Epitope-MHC-II Complexes Mediated CD4+ T Cell Activation and Antigen-Specific Immune Responses , 2012, Pharmaceutical Research.

[149]  Hong Li,et al.  Advanced Functional Materials , 2011 .

[150]  Dong Chen,et al.  The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. , 2010, Biomaterials.

[151]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[152]  T. Merigan,et al.  Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells. , 1998, Cell transplantation.

[153]  Pei-shan Wu,et al.  Biochemical and Biophysical Research Communications , 1960, Nature.

[154]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .